Industry Strength Score
21/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
ADAPTIVE BIOTECHNOLOGIES (ADPT) Stock Price & Overview
NASDAQ:ADPT • US00650F1093
Current stock price
14.1 USD
+0.57 (+4.21%)
At close:
14.1 USD
0 (0%)
After Hours:
The current stock price of ADPT is 14.1 USD. Today ADPT is up by 4.21%. In the past month the price decreased by -2.29%. In the past year, price increased by 43.29%.
ADPT Key Statistics
52-Week Range8.375 - 20.76
Current ADPT stock price positioned within its 52-week range.
1-Month Range12.36 - 15.6125
Current ADPT stock price positioned within its 1-month range.
- Market Cap
- 2.171B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.40
- Dividend Yield
- N/A
ADPT Stock Performance
Today
+4.21%
1 Week
+2.03%
1 Month
-2.29%
3 Months
-23.78%
Longer-term
6 Months -18.78%
1 Year +43.29%
2 Years +438.17%
3 Years +97.48%
5 Years -66.11%
10 Years N/A
ADPT Stock Chart
ADPT Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to ADPT. When comparing the yearly performance of all stocks, ADPT turns out to be only a medium performer in the overall market: it outperformed 58.08% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
ADPT Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ADPT. ADPT may be in some trouble as it scores bad on both profitability and health.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
ADPT Earnings
On February 5, 2026 ADPT reported an EPS of -0.09 and a revenue of 71.68M. The company beat EPS expectations (51.32% surprise) and beat revenue expectations (18.33% surprise).
Next Earnings DateMay 5, 2026
Last Earnings DateFeb 5, 2026
PeriodQ4 / 2025
EPS Reported-$0.09
Revenue Reported71.681M
EPS Surprise 51.32%
Revenue Surprise 18.33%
ADPT Forecast & Estimates
14 analysts have analysed ADPT and the average price target is 21.27 USD. This implies a price increase of 50.88% is expected in the next year compared to the current price of 14.1.
For the next year, analysts expect an EPS growth of -23.67% and a revenue growth 6.68% for ADPT
Analysts
Analysts84.29
Price Target21.27 (50.85%)
EPS Next Y-23.67%
Revenue Next Year6.68%
ADPT Index Membership
ADPT is currently included in the following stock indexes tracked on ChartMill.
ADPT Financial Highlights
Over the last trailing twelve months ADPT reported a non-GAAP Earnings per Share(EPS) of -0.4. The EPS increased by 63.3% compared to the year before.
Income Statements
Revenue(TTM)276.98M
Net Income(TTM)-59.50M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -11.6% | ||
| ROE | -27.19% | ||
| Debt/Equity | 0.58 |
Chartmill High Growth Momentum
EPS Q2Q%60.87%
Sales Q2Q%51.04%
EPS 1Y (TTM)63.3%
Revenue 1Y (TTM)54.77%
ADPT Ownership
Ownership
Inst Owners100.75%
Shares153.98M
Float150.72M
Ins Owners2.2%
Short Float %5.67%
Short Ratio4.47
ADPT Industry Overview
ADPT operates in the Life Sciences Tools & Services sub-industry within the Health Care sector. This group contains 51 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Growth Score
54/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
40%
Outperformed 40% of sub-industries
3 Month Rank
8%
Outperformed 8% of sub-industries
6 Month Rank
11%
Outperformed 11% of sub-industries
Industry Fundamentals & Breadth
- Members
- 51
- New Highs
- 0%
- New Lows
- 5.9%
- Average ROE
- 14.9%
- Average Profit Margin
- 15.8%
- Average Operating Margin
- 18.7%
- Average P/E
- 33.4
- Average Fwd P/E
- 28.9
- Average Debt/Equity
- 0.8
ADPT Competitors/Peers
The largest stocks on the US markets in the "Life Sciences Tools & Services" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| TMO | THERMO FISHER SCIENTIFIC INC | 17.68 | 173.272B | ||
| DHR | DANAHER CORP | 19.44 | 126.537B | ||
| BRKRP | BRUKER CORP - BRKR 6 3/8 09/01/28 | 135.66 | 41.885B | ||
| A | AGILENT TECHNOLOGIES INC | 17.2 | 31.453B | ||
| WAT | WATERS CORP | 21.27 | 28.678B | ||
| IQV | IQVIA HOLDINGS INC | 12.35 | 26.299B | ||
| MTD | METTLER-TOLEDO INTERNATIONAL | 27.18 | 25.113B | ||
| WST | WEST PHARMACEUTICAL SERVICES | 33.11 | 21.29B | ||
| ILMN | ILLUMINA INC | 24.22 | 18.285B | ||
| MEDP | MEDPACE HOLDINGS INC | 21.63 | 11.812B | ||
| RVTY | REVVITY INC | 15.74 | 9.197B | ||
| TEM | TEMPUS AI INC-CL A | N/A | 8.974B | ||
| TECH | BIO-TECHNE CORP | 24.9 | 8.128B |
Related stock screener links
View all stocks in the Life Sciences Tools & Services Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ADPT
Company Profile
Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. The company is headquartered in Seattle, Washington and currently employs 624 full-time employees. The company went IPO on 2019-06-27. The firm is focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. The company applies its platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across its two business segments: Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic test, offered to clinicians. The IM business focuses on the discovery and development of transformative immune-based therapies in the treatment of patients with cancer and autoimmune diseases.
Company Info
IPO: 2019-06-27
ADAPTIVE BIOTECHNOLOGIES
1165 Eastlake Ave E
Seattle WASHINGTON 98102 US
CEO: Chad Robins
Employees: 624
Phone: 12066590067
ADAPTIVE BIOTECHNOLOGIES / ADPT FAQ
Can you describe the business of ADAPTIVE BIOTECHNOLOGIES?
Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. The company is headquartered in Seattle, Washington and currently employs 624 full-time employees. The company went IPO on 2019-06-27. The firm is focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. The company applies its platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across its two business segments: Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic test, offered to clinicians. The IM business focuses on the discovery and development of transformative immune-based therapies in the treatment of patients with cancer and autoimmune diseases.
What is the current price of ADPT stock?
The current stock price of ADPT is 14.1 USD. The price increased by 4.21% in the last trading session.
Does ADAPTIVE BIOTECHNOLOGIES pay dividends?
ADPT does not pay a dividend.
What is the ChartMill technical and fundamental rating of ADPT stock?
ADPT has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the analyst forecast for ADPT stock?
14 analysts have analysed ADPT and the average price target is 21.27 USD. This implies a price increase of 50.88% is expected in the next year compared to the current price of 14.1.
How is the valuation of ADAPTIVE BIOTECHNOLOGIES (ADPT) based on its PE ratio?
ADAPTIVE BIOTECHNOLOGIES (ADPT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.4).
Would investing in ADAPTIVE BIOTECHNOLOGIES be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on ADPT.